1215-98-1

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.

Explanation

This describes the arrangement of atoms and the type of chemical bonds in the compound.

Explanation

These are the specific functional groups present in the compound that give it its unique chemical properties.

Explanation

It is classified as an organic compound because it contains carbon and hydrogen atoms.

Explanation

The compound is used as a starting material for the synthesis of various compounds in different industries.

Explanation

It can be used as a reagent to facilitate specific chemical reactions and as a starting material for the production of dyes and pigments.

Explanation

The compound has potential applications in these fields due to its unique chemical properties and structure.

Explanation

The physical properties such as melting point, boiling point, density, and solubility are not mentioned in the material provided.

Explanation

The chemical properties such as reactivity, stability, and polarity are not mentioned in the material provided.

Chemical Structure

1-[4-(4-aminophenoxy)-phenyl]-ethanone

Functional Groups

Ketone, Phenyl ring, Amino-phenoxy substituent

Classification

Organic compound

Applications

Building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Utilization

Reagent in organic reactions, starting material for the production of dyes and pigments

Potential Applications

Medicinal chemistry, materials science, drug discovery

Upstream product

• 75919-92-5 1-(4-(4-nitrophenoxy)phenyl)ethanone 
• 99-93-4 4-Hydroxyacetophenone 
• 350-46-9 4-Fluoronitrobenzene 
• 620-88-2 4-nitrophenyl phenyl ether 

Downstream Products

• 1426925-09-8 1-(4-(4-(2-chloro-5-((1S,2S,3S,4R,5S)-2,3,4-trihydroxy-1-(hydroxylmethyl)-6,8-dioxabicyclo[3.2.1]octan-5-yl)benzyl)phenoxy)phenyl)ethanone O-ethyl oxime 
• 852631-01-7 1-[4-(4-iodophenoxy)phenyl]ethan-1-one 
• 1426925-10-1 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)phenyl)ethanone 
• 1426925-11-2 (1R,2S,35,4R,5S)-1-(acetoxymethyl)-5-(3-(4-(4-acetylphenoxy)benzyl)-4-chlorophenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl triacetate 
• 1426925-12-3 (1R,2S,3S,4R,5S)-1-(acetoxymethyl)-5-(4-chloro-3-(4-(4-(1-(ethoxyimino)ethyl)phenoxy)benzyl)phenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl triacetate 

Relevant academic research and scientific papers

A new cobalt triangular prism supramolecular flask: Encapsulation of a quinhydrone cofactor for hydrogenation of nitroarenes with high selectivity and efficiency

A new M6L3 metal-organic triangular prism host Co–L1 was synthesized that contains a sufficiently large cavity for encapsulation of a quinhydrone (QHQ) electron transporter to form charge-transfer complexes for accelerating electron delivery. Through the strong coordinating ability of the ONP chelator, a suitable redox potential was obtained for the combination of light-driven proton reduction with the selective hydrogenation of nitro groups. The experimental results showed that the regulation of redox potential is very beneficial for hydrogen production and that the introduction of QHQ accelerates electron transfer and increases the reaction rate. Control experiments based on an inhibitor and a mononuclear compound resembling the cobalt corner of the triangular prism suggest enzyme-like behaviour. This synthetic platform, in which the supramolecular systems exhibit high activity and stability, provides an alternative strategy to selectively hydrogenate nitroarenes using light as a clean energy source.

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synt

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the sy

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.